Columbia Study: SSRI Antidepressants May Accelerate Degeneration in Diseased Heart Valves

Columbia University researchers have discovered a significant link between the most frequently prescribed antidepressants and the accelerated degeneration of heart valves. Scientists closely examined the medical records and tissue biopsies of 9,000 patients to investigate the effects of serotonin signaling on heart health. The research points to a distinct risk factor, particularly in degenerative mitral regurgitation (DMR), which is one of the most common heart valve diseases. The results indicate that patients taking selective serotonin reuptake inhibitors (SSRIs) who also carry a specific gene variant that transports serotonin may require surgery to completely replace or repair the valve at younger ages. This finding raises new and important scientific questions regarding the relationship between psychiatric medications and cardiology.

The mitral valve is located between the heart's left atrium and left ventricle, acting as a door that prevents oxygen-rich blood from flowing backward with each heartbeat. In the case of degenerative mitral regurgitation, the thin leaflets of this valve thicken, stretch, and fail to function properly. This structural deterioration causes the blood to leak in the wrong direction, leading to increased pressure toward the lungs and forcing the heart to work harder to pump the normal volume forward. In the early stages of the disease, many patients may not feel any symptoms, but over time, serious problems such as fatigue, shortness of breath, atrial fibrillation, and ultimately heart failure emerge. Although medications can alleviate these symptoms, they cannot repair the physical tissue of the valve, making surgical intervention inevitable when the condition becomes severe.

Serotonin is a chemical messenger that performs many different functions in the body, such as regulating mood, sleep, digestion, memory, and blood clotting. SSRIs (such as Prozac and Zoloft) enhance the effect of this chemical in the brain by preventing the reuptake of serotonin through carrier proteins (SERT) on the surface of cells. To understand what consequences this mechanism, while beneficial in the brain, might have on an already diseased mitral valve, the research team at Columbia conducted laboratory experiments. It was observed that the heart valves of genetically modified mice lacking the SERT gene and normal mice given high doses of SSRIs thickened significantly. Similarly, in human heart valve cells grown in a laboratory setting, low SERT activity was found to increase the production of collagen, which excessively stiffens and distorts the tissue.

Scientists investigated the role of a specific DNA variant called 5-HTTLPR, which affects the activity of the serotonin transporter, in this process. It was determined that patients with certain gene variants had higher surgery rates, and their valve cells exhibited much stronger responses to serotonin in laboratory tests. These data reveal that having an already degrading heart valve, a genetic structure that suppresses carrier gene activity, and the use of SSRI medications that further amplify this effect could pose a combined risk. However, the researchers specifically emphasize that mitral valve cells taken from healthy individuals are not harmed by normal SSRI doses. Because a healthy heart valve can likely tolerate low serotonin transporter activity without damage, these medications are considered extremely safe for most patients.

In light of these findings, experts remind us that patients taking antidepressants should not abruptly discontinue their treatments, as doing so carries its own significant health risks. Instead, it is recommended that patients diagnosed with degenerative mitral regurgitation have their genetic predispositions checked via a simple blood test or a buccal swab. Cardiac patients carrying the risky gene variant may require closer echocardiographic monitoring or earlier surgical planning. Furthermore, it is noted that such a genetic test could provide valuable data for individuals with progressive heart valve disease to discuss with their physicians regarding whether to change their antidepressant classes. Although these recommendations are not yet an official medical guideline or rule, they stand out in the medical world as a new study demonstrating the importance of early diagnosis in preventing heart failure.